Interaction between saquinavir and antimycotic drugs on C. albicans and C. neoformans strains

Pharmacological Research

Volumn 50, Issue 6, 2004, Pages 605-610

  Casolari, Chiara ^a   Rossi, Tiziana ^a   Baggio, Giosué ^a   Coppi, Andrea ^a   Zandomeneghi, Ginevra ^a   Ruberto, Antonio Ippazio ^a   Farina, Claudio ^b   Fabio, Giuliana ^a   Zanca, Andrea ^c   Castelli, Mario ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

C. albicans; C. neoformans; Drug combination; Sabouraud; Saquinavir; Synergism; YNB medium

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; MICONAZOLE; PROTEINASE INHIBITOR; SAQUINAVIR;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS GROWTH; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; SAQUINAVIR;

EID: 6344280335     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.06.008     Document Type: Article

References (39)

1. D. Amstrong Fungal and bacterial infections associated with AIDS Curr Opin Infect Dis 2 1989 234 238
2. R. Diamond The growing problem of mycosis in patients infected with the human immunodeficiency virus Rev Infect Dis. 13 1991 480 486
3. L. Chen, E.S. Blank, and A. Casadevall Extracellular proteinase activity of Cryptococcus neoformans Clin Diagn Lab Immunol. 3 1996 570 574
4. M. Borg-von Zeppelin, I. Meyer, R. Thomssen, R. Wurzner, D. Sanglard, and A. Telenti HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic protease J Invest Dermatol. 113 1999 747 751
5. U. Malhotra, M.M. Berrei, Y. Huang, J. Maree, D.J. Brown, and S. Ap Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection J Infect Dis. 181 2000 121 131
6. C.M. Mastroianni, M. Lichtner, F. Mengoni, C. D'Agostino, G. Forcina, and G. D'Ettorre Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1 infected patients AIDS 13 1999 883 890
7. I. Mezzaroma, M. Carlesimo, E. Pinter, C. Alario, G. Sacco, and D. Santini Muratori Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease AIDS 13 1999 1187 1193
8. C. Munro, and B. Hube Anti-fungal therapy at the HAART of viral therapy Trends Microbiol 10 2002 173 177
9. A. Cassone, F. De Bernardis, A. Torasantucci, E. Tacconelli, M. Tumbarello, and R. Cauda In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors J Infect Dis. 180 1999 448 453
10. A. Gruber, C. Speth, E. Lukasser-Vogl, R. Zangerle, M. Borg-von Zepelin, and M.P. Dierich Human immunodeficiency virus type 1 protease inhibitor attenuate Candida albicans virulence properties in vitro Immunopharmacology 41 1999 227 234
11. M. Monod, M. Borg-von Zepelin, A. Telenti, and D. Sanglard The inhibition of Candida albicans secreted aspartic proteases by three different HIV protease inhibitors Dermatology 198 1999 412 414
12. M. Schaller, N. Krnjaic, M. Niewerth, G. Hamm, B. Hube, and H.C. Korting Effect of antimicotic agents on the activity of aspartyl proteinases secreted by Candida albicans J Med Microbiol. 52 2003 247 249
13. H.C. Korting, M. Schaller, G. Eder, G. Hamm, U. Bohmer, and B. Hube Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients Antmicrob Agents Chemother. 43 1999 2038 2042
14. J. Bektic, C.P. Lell, A. Fuchs, H. Stoiber, C. Speth, and C. Lass-Flor HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro FEMS Immunol Med Microbiol. 31 2001 65 71
15. T. Wu, K. Wright, S.F. Hurst, and C.J. Morrison Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in sub-inhibitory concentrations of fluconazole Antimicrob Agents Chemother. 44 2000 1200 1208
16. J.R. Naglik, S.J. Challacombe, and B. Hube Candida albicans secreted aspartyl proteinases in virulence and pathogenesis Microbiol Mol Biol Rev. 67 2003 400 428
17. B. Hube, and J. Naglik Candida albicans proteinases: resolving the mystery of a gene family Microbiology 147 2001 1997 2005
18. A. Gruber, C.P. Lell, M. Spruth, C. Lass-Florl, C. Speth, and H. Stoiber HIV-1 and its transmembrane protein gp41 bind to different Candida species modulating adhesion FEMS Immunol Med Microbiol. 37 2003 77 83
19. M. Bein, M. Schaller, and H.C. Korting The secreted asparyl proteinases as a new target in the therapy of candidiasis Curr Drug Targets 3 2002 351 357
20. L. Hoegl, E. Thoma-Greber, M. Rocken, and H.C. Korting HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2 years study Mycoses 41 1998 321 325
21. S. Mata-Essayag, S. Magaldi, C. Hartung de Capriles, L. Deibis, G. Verde, and C. Perez "In vitro" antifungal activity of protease inhibitors Mycopathologia 152 2001 135 142
22. M.T. Blanco, C. Hurtado, C. Perez-Giraldo, F.J. Moran, C. Gonzales-Velasco, and A.C. Gomez-Garcia Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases Med Mycol. 41 2003 167 170
23. M. Schaller, N. Krnjaic, M. Niewerth, G. Hamm, B. Hube, and H.C. Korting Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans J Med Microbiol. 52 2003 247 249
24. P. Ruma-Hayes, A.G. Brownlee, and T.C. Sorrell A rapid method for detecting extracellular proteinase activity in Cryptococcus neoformans and a survey of 63 isolates J Med Microbiol. 49 2000 733 737
25. M. Rhunke, A. Schmidt-Westhausen, and M. Trautmann Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection Mycoses 39 1996 47 50
26. E. Krajewska-Kulak, and W. Niczyporuk In vitro synergistic activity of ketoconazole with valproic acid against Candida species Arzneimittelforschung 46 1996 934 936
27. F. Mignini, M. Prenna, S. Olivieri, E. Cammarata, E. Falcioni, and B. Dainell Comparative activity in different media of ketoconazole, miconazole and amphothericin B against Candida lusitaniae and sucrose-negative Candida tropicalis Chemioterapia 7 1988 38 41
28. M.A. Petrou, and D.C. Shanson Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media J Antimicrob Chemother 46 2000 815 818
29. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Tentative Guidelines M26-27. Villanova, PA: NCCLS, 1992.
30. D.J. Krogstad, and R.C. Möellering Combination of antibiotic mechanism of interaction against bacteria Lorian Antibiotics in Laboratory Medicine 1980 The Williams and Wilkins Co Baltimore 298 341
31. C.M. Perry, and S. Noble Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection Drugs 55 1998 461 486
32. D.P. Figgitt, and G.L. Plosker Saquinavir soft-gel capsule: an update review of its use in the management of HIV infection Drugs 60 2000 481 516
33. P. Diz Dios, I. Otero Varela, I. Iglesiais Martin, A. Ocampo Hermida, and C. Martinez Vasquez Failure of indinavir to inhibit Candida albicans in vitro Eur J Clin Microbiol Infect Dis. 18 1999 755 756
34. P.E.O. Williams, G.J. Muirhead, M.J. Madigan, A.M. Mitchell, and T. Shaw Disposition and bioavailability of the HIV-proteinase inhibitor, Ro-31-8959, after single doses in healthy volunteers Br J Clin Pharmacol. 34 1992 155P 156P
35. C.A. Kauffman, and P.L. Carter Antifungal agents in the 1990s. Current status and future developments Drugs 53 1997 539 549
36. C.A. Kauffman Role of azoles in antifungal therapy Clin Infect Dis 22 1996 S148 S153
37. M.L. Sokol-Anderson, J. Brajtburg, and G. Medoff Amphotericin B-induced oxidative damage and killing of Candida albicans J Infect Dis. 154 1986 76 83
38. J.H. Rex, M.G. Rinaldi, and M.A. Pfaller Resistance of C. albicans species to fluconazole Antimicrob Agents Chemother. 39 1995 1 8
39. A. Espinel-Ingroff Clinical relevance of antifungal resistance Infect Dis Clin North Am 11 1997 929 944